Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 1, 2008, Pages 25-33

  Wu, Pei Chang ^a,b   Tai, Ming Hong ^b,c   Hu, Dan Ning ^d   Lai, Chien Hsiung ^a   Chen, Yi Hao ^a   Wu, Yi Chen ^a   Tsai, Chia Ling ^a   Shin, Shyi Jang ^b   Kuo, Hsi Kung ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CELL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR; DIMETHYL SULFOXIDE; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; ROSCOVITINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ASSAY; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL NUCLEUS; CELL POPULATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; FLOW CYTOMETRY; NONHUMAN; PIGMENT CELL; RABBIT; STAINING; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASES; DNA; EPITHELIAL CELLS; FLOW CYTOMETRY; GROWTH INHIBITORS; PIGMENT EPITHELIUM OF EYE; PROTO-ONCOGENE PROTEINS C-BCL-2; PURINES; RABBITS;

EID: 38549144644     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0044     Document Type: Article

References (43)

1. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90:121-125, 1983.
2. Chignell, A.H., Fison, L.G., Davies, E.W., et al. Failure in retinal detachment surgery. Br. J. Ophthalmol. 57:525-530, 1973.
3. Mandelcorn, M.S., Machemer, R., Fineberg, E., et al. Proliferation and metaplasia of intravitreal retinal pigment epithelium cell autotransplants. Am. J. Ophthalmol. 80:227-237, 1975.
4. Vinores, S.A., Campochiaro, P.A., and Conway, B.P. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest. Ophthalmol. Vis. Sci. 31:14-28, 1990.
5. Clarkson, J.G., Green, W.R., and Massof, D. A histopathologic review of 168 cases of preretinal membrane. Am. J. Ophthalmol. 84:1-17, 1977.
6. Machemer, R., van Horn, D., and Aaberg, T.M. Pigment epithelial proliferation in human retinal detachment with massive periretinal proliferation. Am. J. Ophthalmol. 85:181-191, 1978.
7. Morino, I., Hiscott, P., McKechnie, N., et al. Variation in epiretinal membrane components with clinical duration of the proliferative tissue. Br. J. Ophthalmol. 74:393-399, 1990.
8. Mueller-Jensen, K., Machemer, R., and Azarnia, R. Autotransplantation of retinal pigment epithelium in intravitreal diffusion chamber. Am. J. Ophthalmol. 80:530-537, 1975.
9. Sherr, C.J. Cancer cell cycles. Science 274:1672-1677, 1996.
10. Baldin, V., Lukas, J., Marcote, M.J., et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7:812-821, 1993.
11. Sherr, C.J. Mammalian G1 cyclins. Cell 73:1059-1065, 1993.
12. Meijer, L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell. Biol. 6:393-397, 1996.
13. De Azevedo, W.F., Leclerc, S., Meijer, L., et al. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243:518-526, 1997.
14. Meijer, L., Borgne, A., Mulner, O., et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5. Eur. J. Biochem. 243:527-536, 1997.
15. Shankland, S.J., Hamel, P., and Scholey, J.W. Cyclin and cyclin-dependent kinase expression in the remnant glomerulus. J. Am. Soc. Nephrol. 8:368-375, 1997.
16. Stovickova, J., and Havranova, M. The effect of olomoucine and roscovitine on proliferation activity of human diploid fibroblasts from noninflamed and inflamed tissue and chondrocytes from osteoarthritic cartilage. Rheumatologia 13:157-165, 1999.
17. Senderowicz, A.M. Small-molecule, cyclin-dependent kinase modulators. Oncogene 22:6609-6620, 2003.
18. Rossi, A.G., Sawatzky, D.A., Walker, A., et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 12:1056-1064, 2006.
19. Park, D.S., Farinelli, S.E., and Greene, L.A. Inhibitors of cyclin-dependent kinases promote survival of postmitotic neuronally differentiated PC12 cells and sympathetic neurons. J. Biol. Chem. 271:8161-8169, 1996.
20. Osuga, H., Osuga, S., Wang, F., et al. Cyclin-dependent kinases as a therapeutic target for stroke. Proc. Natl. Acad. Sci. U.S.A. 97:10254-10259, 2000.
21. Elledge, S.J. Cell cycle checkpoints: Preventing an identity crisis. Science 274:1664-1672, 1996.
22. Hall, M., and Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:67-108, 1996.
23. Meijer, L., and Kim, S.H. Chemical inhibitors of cyclin-dependent kinases. Meth. Enzymol. 283:113-128, 1997.
24. Sherr, C.J., and Roberts, J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149-1163, 1995.
25. Havlicek, L., Hanus, J., Vesely, J., et al. Cytokinin-derived, cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 40:408-412, 1997.
26. Iseki, H., Ko, T.C., Xue, X.Y., et al. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery 122:187-194; discussion 194-195, 1997.
27. Pippin, J.W., Qu, Q., Meijer, L., et al. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist. J. Clin. Invest. 100:2512-2520, 1997.
28. Mihara, M., Shintani, S., Kiyota, A., et al. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int. J. Oncol. 21:95-101, 2002.
29. Adams, J.M., and Cory, S. The Bcl-2 protein family: Arbiters of cell survival. Science 281:1322-1326, 1998.
30. Burlacu, A. Regulation of apoptosis by Bcl-2 family proteins. J. Cell. Mol. Med. 7:249-257, 2003.
31. Oltvai, Z.N., Milliman, C.L., and Korsmeyer, S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619, 1993.
32. LeBlanc, H., Lawrence, D., Varfolomeev, E., et al. Tumor-cell resistance to death receptor - induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8:274-281, 2002.
33. Wesierska-Gadek, J., Gueorguieva, M., and Horky, M. Dual action of cyclin-dependent kinase inhibitors: Induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol. J. Pharmacol. 55:895-902, 2003.
34. Barrada, A., Peyman, G.A., Case, J., et al. Evaluation of intravitreal 5-fluorouracil, vincristine, VP 16, doxorubicin, and thiotepa in primate eyes. Ophthalmic Surg. 15:767-769, 1984.
35. Wu, W.C., Kao, Y.H., and Hu, D.N. A comparative study of effects of antiproliferative drugs on human retinal pigment epithelial cells in vitro. J. Ocul. Pharmacol. Ther. 18:251-264, 2002.
36. Asaria, R.H., Kon, C.H., Bunce, C., et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology 108:1179-1183, 2001.
37. Charteris, D.G., Aylward, G.W., Wong, D., et al. A randomized, controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 111:2240-2245, 2004.
38. Garcia, R.A., Sanchez, J.G., and Arevalo, J.F. Combined 5-fluorouracil, low-molecular-weight heparin, and silicone oil in the management of complicated retinal detachment with proliferative vitreoretinopathy grade C. Ophthalmic Surg. Lasers Imaging 38:276-282, 2007.
39. Wickham, L., Bunce, C., Wong, D., et al. Randomized, controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 114:698-704, 2007.
40. Arroyo, J.G., Yang, L., Bula, D., et al. Photoreceptor apoptosis in human retinal detachment. Am. J. Ophthalmol. 139:605-610, 2005.
41. Tang, X., Wang, X., Gong, X., et al. Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J. Neurosci. 25:4823-4834, 2005.
42. Gillardon, F., Schrattenholz, A., and Sommer, B. Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis. J. Cell. Biochem. 95:817-826, 2005.
43. Di Giovanni, S., Movsesyan, V., Ahmed, F., et al. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc. Natl. Acad. Sci. U.S.A. 102:8333-8338, 2005.